Bendamustine HCl

盐酸苯达莫司汀,盐酸苯达莫西丁,SDX-105,EP-3101,EP3101,EP 3101,Cytostasane HCl

Bendamustine hydrochloride是DNA损伤剂,IC50为50 μM。

目录号
EY0291
EY0291
纯度
99.15%
99.15%
规格
25 mg
100 mg
原价
460
1280
售价
460
1280
库存
现货
现货
订购
订购
订购
订购
订购
订购
  • 生物活性

    Bendamustine HCL is a DNA-damaging agent with IC50 of 50 μM in cell-free assay.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

    0 μM -100 μM

  • 动物实验

    25 mg/kg静脉注射

  • 不同实验动物依据体表面积的等效剂量转换表(数据来源于FDA指南)

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 AKm系数


    例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。


  • 参考文献

    [1] Leoni LM, et al. Clin Cancer Res. 2008, 14(1), 309-317.

    分子式
    C16H22Cl3N3O2
    分子量
    394.72
    CAS号
    3543-75-7
    储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂(常温)
    DMSO
    79 mg/mL
    Water
    15 mg/mL
    Ethanol
    20 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT00139841 Non-Hodgkin's Lymphoma Drug: Bendamustine HCl Cephalon|Teva Pharmaceutical Industries Phase 3 2005-10-01 2014-05-08
    NCT00705250 Hodgkin's Disease|Lymphoma Drug: bendamustine hcl Memorial Sloan Kettering Cancer Center|Cephalon Phase 2 2008-06-01 2017-01-18
    NCT00867503 Ovarian Cancer Drug: Bendamustine HCL University of Arizona|Cephalon Phase 2 2009-02-01 2015-12-02
    NCT00959686 T-cell Lymphoma Drug: Bendamustine French Innovative Leukemia Organisation|Mundipharma Pte Ltd. Phase 2 2009-09-01 2013-02-11
    NCT01500083 Indolent Non-Hodgkin's Lymphoma|Chronic Lymphocytic Leukemia Drug: Bendamustine at a dose of 100 mg/m2|Drug: Bendamustine at a dose of 120 mg/m2 Lundbeck Canada Inc. Phase 3 2012-03-01 2014-10-16
    NCT01626352 Diffuse Large B-Cell Lymphoma Drug: Bendamustine|Drug: Ofatumumab SCRI Development Innovations, LLC|Novartis|GlaxoSmithKline|Cephalon Phase 2 2012-08-01 2017-02-14
    NCT00076349 Non-Hodgkin's Lymphoma Drug: bendamustine and rituximab Cephalon|Teva Pharmaceutical Industries Phase 2 2004-04-01 2014-05-08
    NCT00947388 Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage III Chronic Lymphocytic Leukemia|Stage III Small Lymphocytic Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Small Lymphocytic Lymphoma Drug: Bendamustine Hydrochloride|Biological: Alemtuzumab Case Comprehensive Cancer Center|Cephalon Phase 1 2008-11-01 2013-08-20
    NCT01010568 Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma Drug: Ofatumumab and Bendamustine Georgetown University|GlaxoSmithKline|Cephalon Phase 2 2010-04-01 2015-11-10
    NCT01596621 Non-Hodgkin Lymphoma Drug: Bendamustine hydrochloride Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries Phase 3 2012-07-01 2016-12-01
    NCT01929265 Indolent Non-follicular|Non-Hodgkin's Lymphoma Drug: Bendamustine Fondazione Italiana Linfomi ONLUS Phase 2 2011-01-01 2017-03-22
    NCT01022021 Lymphoma Drug: Rituximab|Drug: Bendamustine University of Kansas Medical Center|Cephalon Early Phase 1 2010-01-01 2017-01-06
    NCT01152203 Advanced Cancer Drug: Bendamustine|Drug: Bevacizumab M.D. Anderson Cancer Center|Cephalon|National Comprehensive Cancer Network Phase 1 2010-06-01 2015-11-16
    NCT02315157 Multiple Myeloma|Plasma Cell Leukemia Drug: Bendamustine Sidney Kimmel Cancer Center at Thomas Jefferson University|Thomas Jefferson University Phase 1 null 2016-10-19
    NCT01077518 Lymphoma, Follicular Drug: Ofatumumab and Bendamustine infusions (Arm A)|Drug: Bendamustine infusion (Arm B) Novartis Pharmaceuticals|Novartis Phase 3 2010-08-01 2016-08-07
    NCT00426855 Lymphoma, Non-Hodgkin Drug: Bendamustine|Drug: Bortezomib Peter Moosmann|Kantonsspital Aarau Phase 1|Phase 2 2007-01-01 2015-04-02
    NCT01296256 Bendamustine|Conditioning Therapy|Autologous Stem Cell Transplant|Aggressive Non Hodgkin's Lymphoma Drug: Bendamustine-EAM Grupo Espa帽ol de Linfomas y Transplante Aut贸logo de M茅dula 脫sea Phase 2 2011-05-01 2016-02-15
    NCT00831597 Diffuse Large B-Cell Lymphoma Drug: bendamustine|Drug: rituximab Pharmatech|Cephalon Phase 2 2008-11-01 2016-04-18
    NCT01315873 Multiple Myeloma Drug: Bendamustine|Drug: Bortezomib New York University School of Medicine|Cephalon Phase 2 2011-09-01 2016-09-08
    NCT01657331 Hodgkin Lymphoma|Anaplastic Large Cell Lymphoma Drug: Brentuximab Vedotin|Drug: Bendamustine|Drug: Neulasta Owen A. O'Connor|British Columbia Cancer Agency|Princess Margaret Hospital, Canada|Columbia University Phase 1|Phase 2 2012-07-01 2017-02-01

    注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 :
  • 收件地址 :
  • 电话号码 :
  • 单位名称 :
  • 产品货号 :
  • 产品规格 :
  • 发票抬头以及单位税号 :